4004 ESC Guidelines label use of medication should be limited to situations where it is in
the patient's interest to do so, with regard to the quality, safety, and efficacy of care, and only …

for digital applications (smartphones, etc.). These versions are abridged and thus, for more
detailed information, the user should always access to the full text version of the guidelines …

The recommendations listed in this clinical practice guideline are, whenever possible,
evidence-based. An initial extensive evidence review, which included literature derived from …

Sarcoidosis is a systemic granulomatous disease of unknown cause. Sarcoidosis involving
the heart, ie, cardiac sarcoidosis, affects the prognosis of patients significantly as it may lead …

The recommendations listed in this guideline are, whenever possible, evidence based. An
initial extensive evidence review, which included literature derived from research involving …

Sarcoidosis is a complex disease with heterogeneous clinical presentations that can affect
virtually any organ. Although the lung is typically the most common organ involved …

Clinically manifest cardiac involvement occurs in perhaps 5% of patients with sarcoidosis.
The 3 principal manifestations of cardiac sarcoidosis (CS) are conduction abnormalities …

Developing consensus recommendations for rare diseases requires adapting the
methodology for preparing traditional guidelines for clinical practice. The most obvious …

Background—This study was designed to assess the epidemiology, characteristics, and
outcome of cardiac sarcoidosis (CS) in Finland. Methods and Results—We identified in …

Objectives: This study sought to relate imaging findings on positron emission tomography
(PET) to adverse cardiac events in patients referred for evaluation of known or suspected …